cyclovirobuxine-d and Heart-Failure

The effect of Cyclovirobuxine D, an active ingredient from Buxus microphylla, was investigated in the potential prevention of cardiac dysfunction in rats with congestive heart failure. Heart failure was induced by left coronary artery occlusion and verified using echocardiography. Cyclovirobuxine D was administered for 30 days (0.5, 1.0 and 2.0mg/kg, ig) and mortality, cardiac function, hemodynamics, microcirculation, histology and ultrastructure assessments were observed. Results from the present study suggest that Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction and supports the potential for Cyclovirobuxine D as a new therapy for heart failure.

Topics: Animals; Buxus; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Echocardiography; Heart; Heart Failure; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley

The patients with congestive heart failure which were treated by combination of digoxin with cyclovirobuxine D were described, with good result, of which prominating effect was 45.5%. Researchful result of 11 patients showed serum concentration of digoxin before and after combined treatment was not obviously different (P less than 0.05). Basis of pharmacokinetics was provided for using combined treatment of these drugs with long time and greater safeness.

Topics: Adult; Aged; Cardiovascular Agents; Digoxin; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Heart Failure; Humans; Male; Middle Aged